The latest report from a group financed and backed by the pharmaceutical industry “continues to misrepresent” the 340B Drug Pricing Program and its “successful 25-year history of helping hospitals stretch scarce financial resources to expand and improve access to lifesaving prescription drugs and comprehensive health services,” AHA Executive Vice President Tom Nickels writes today in an AHA Stat blog post. Nickels says the report “attempts to mislead the debate by comparing changes in the ‘charity care’ provided by a small sample size of 160 disproportionate share hospitals (out of 2,448 hospitals) that participate in the 340B program,” and he highlights the many benefits 340B hospitals provide to the patients and communities they serve. "We hope policymakers won’t be diverted by this self-serving report from the important job of finding solutions to bring down the exorbitant cost of many prescription drugs that is threatening the availability of life-saving medications for millions of Americans,” Nickels writes.

Related News Articles

Headline
Continued rising drug prices, as well as shortages for many critical medications, are disrupting patient care and forcing hospitals to delay infrastructure and…
Headline
AHA said it generally supports CMS’ efforts to grant greater state-level flexibility and reduce regulatory burden, but urged the agency to ensure Medicaid…
Headline
Virginia hospitals and health systems provided nearly $3.3 billion in community benefit and other support in 2017, according to the latest annual report by the…
Perspective
We’re 11 days into 2019 … we’ve returned to a divided government …and the partial government shutdown continues.
Headline
The House of Representatives last night authorized its general counsel to intervene to defend the Affordable Care Act in a federal court case in Texas, and in…
Headline
Accountable care organizations interested in participating in the redesigned Medicare Shared Savings Program beginning July 1 must submit their notices of…